Lutetium Lu-177 vipivotide tetraxetan

Is Lutetium Lu-177 vipivotide tetraxetan safe?

Trial and label safety data

In VISION, the most common adverse events were fatigue, dry mouth, nausea, anemia and loss of appetite. Grade 3 or higher events occurred in 53 percent of the radioligand arm. In controls it was 38 percent. Low blood counts drove the gap. The label warns of myelosuppression. It warns of kidney toxicity. It warns of radiation exposure to others. It advises contraception. The drug can harm sperm and a fetus. ¹²

Dry mouth is more frequent than with lutetium dotatate. Salivary glands carry PSMA. Secondary cancers from marrow irradiation are a theoretical concern. Follow-up so far is too short to size that risk. ²

Read the full Lutetium Lu-177 vipivotide tetraxetan page

Reference information only, not medical advice. Drawn from the Lutetium Lu-177 vipivotide tetraxetan article, fact-checked against the cited sources. No dosing anywhere on this site.